Printer Friendly

A. L. LABORATORIES ANNOUNCES FIRST APPROVAL FOR ITS DENTURE STOMATITIS TREATMENT PRODUCT

 FORT LEE, N.J., March 24 /PRNewswire/ -- A. L. Laboratories, Inc. (NYSE: BMD) today announced that its international pharmaceutical subsidiary, Dumex Ltd., has received approval in Sweden to manufacture and market its new product, DumicoatR. This is the first regulatory approval the Company has received for a patented, sustained-release product for treatment of the fungal disease afflicting denture wearers, known as denture stomatitis. The Company will begin marketing Dumicoat in Sweden in the first quarter of 1993.
 Jeffrey E. Smith, executive vice president of A. L. Laboratories, Inc. said, "Dumicoat is the second exciting proprietary Oral Health Care product to result from our international scientific development capabilities. Elyzol DentalgelR, our periodontal disease treatment product, received its initial European approval in December 1992.
 "Dumicoat utilizes a known anti-fungal in a controlled-release, specially formulated lacquer which is applied directly to the denture plate. This innovative therapeutic approach provides both superior disease treatment, with a significantly lower dosage of active ingredient than all existing treatments, and greatly enhanced patient compliance.
 "In addition to Sweden, registration applications have been filed in Norway, Denmark, Finland, the United Kingdom, Germany, Switzerland, Holland and Ireland. We plan to 'bridge' Dumicoat to the U.S. market, in the same manner we are using with our Elyzol Dentalgel, which is presently undergoing Phase III clinical trials."
 The Company estimates that sales of Dumicoat could reach $25 million in Europe, with a similar sized market potential in the United States.
 A. L. Laboratories is a multinational manufacturer and marketer of specialized and value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Illinois, Maryland, New Jersey, New York, North Carolina, Washington State, Denmark and Indonesia.
 -0- 3/24/93
 /CONTACT: Iris Daniels of A. L. Laboratories, Inc., 201-947-7774; or David Walke of Morgen-Walke Associates, 212-986-5900, for A. L. Laboratories, Inc./
 (BMD)


CO: A. L. Laboratories, Inc. ST: New Jersey IN: HEA SU: PDT

LR -- NY017 -- 9004 03/24/93 09:54 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 24, 1993
Words:323
Previous Article:BRILLIANCE CHINA AUTOMOTIVE HOLDINGS LIMITED DECLARES QUARTERLY DIVIDEND
Next Article:DURAKON INDUSTRIES NAMES FISHER AS CHAIRMAN
Topics:


Related Articles
WARNER-LAMBERT - CHURCH & DWIGHT ENTER INTO LICENSING AGREEMENT
A. L. LABORATORIES NAMES CYRILL SIEWERT AS ORAL HEALTH CARE PRESIDENT
A.L. LABORATORIES ANNOUNCES ADDITIONAL APPROVALS FOR ITS ELYZOL DENTALGEL
/C O R R E C T I O N -- A.L. LABORATORIES, INC./
A. L. LABORATORIES ANNOUNCES FDA APPROVAL OF CLOTRIMAZOLE VAGINAL CREAM
A. L. LABORATORIES UPDATES IMPACT OF BUSINESS TRENDS ON COMPANY PERFORMANCE
A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA
Carrington Laboratories Strengthens Oral Product Line

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters